Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model

EJNMMI Research

Volumn 4, Issue 1, 2014, Pages 1-10

  Bison, Sander M ^a   Pool, Stefan E ^a   Koelewijn, Stuart J ^a   van der Graaf, Linda M ^a   Groen, Harald C ^a   Melis, Marleen ^a   de Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

177Lu DOTATATE; Affinitor; Everolimus; Metastasis; RAD001

Indexed keywords

EVEROLIMUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; METASTASIS; PANCREAS CANCER; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RADIOISOTOPE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 84947025820     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/s13550-014-0021-y     Document Type: Article

References (38)

1. Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M: The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.Langenbecks Arch Surg 2011, 396:1145–1156.
2. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG: Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med 2011, 364:514–523.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.J Clin Oncol 2008, 26:3063–3072.
4. Van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ: Peptide-receptor radionuclide therapy for endocrine tumors.Nat Rev Endocrinol 2009, 5:382–393.
5. Kwekkeboom DJ, de Herder WW, van Eijck CHJ, Kam BL, van Essen M, Teunissen JJM, Krenning EP: Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.Semin Nucl Med 2010, 40:78–88.
6. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G: Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study.Eur J Nucl Med Mol Imaging 2011, 38:2125–2135.
7. 3]octreotate.J Clin Oncol 2004, 22:2724–2729.
8. Seeliger H, Guba M, Kleespies A, Jauch K-W, Bruns CJ: Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis.Cancer Metastasis Rev 2007, 26:611–621.
9. Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ: Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer.Clin Cancer Res 2008, 14:892–900.
10. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.Cancer Res 2004, 64:252–261.
11. Pool SE, Bison S, Koelewijn SJ, van der Graaf LM, Melis M, Krenning EP, de Jong M: mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.Cancer Res 2013, 73:12–18.
12. Bernard BF, Krenning E, Breeman WAP, Visser TJ, Bakker WH, Srinivasan A, De Jong M: Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy.Nucl Med Commun 2000, 21:1079–1085.
13. Cutler LS, Rozenski D, Coolens J, Rozing J, Angelillo M, Wayne AL, Fitzgerald KM, Greiner DL: Experimental autoallergic sialadenitis in the LEW rat: I. Parameters of disease induction.Cell Immunol 1991, 135:335–345.
14. Greiner DL, Angelillo M, Wayne AL, Fitzgerald KM, Rozenski D, Cutler LS: Experimental autoallergic sialadenitis in the LEW rat: III. Role of CD4+ T cells in EAS induction.Cell Immunol 1991, 135:354–359.
15. Perlik F, Zidek Z: The susceptibility of several inbred strains of rats to adjuvant-induced arthritis and experimental allergic encephalomyelitis.Z Für Immunitätsforschung Exp Klin Immunol 1974, 147:191.
16. Gasser DL, Palm J, Gonatas NK: Genetic control of susceptibility to experimental allergic encephalomyelitis and the Ag-B locus of rats.J Immunol 1975, 115:431–433.
17. Friedman I, Ron N, Laufer A, Davies AM: Experimental myocarditis: enhancement by the use of pertussis vaccine in Lewis rats.Experientia 1970, 26:1143–1145.
18. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami H-O, Hacker DG, Hoover R, Fraumeni JF Jr: Incidence of cancer among patients with rheumatoid arthritis.J Natl Cancer Inst 1993, 85:307–311.
19. Sakaguchi S, Takahashi T, Yamazaki S, Kuniyasu Y, Itoh M, Sakaguchi N, Shimizu J: Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity.Microbes Infect 2001, 3:911–918.
20. Kwekkeboom D, Bakker W, Kooij P, Konijnenberg M, Srinivasan A, Erion J, Schmidt M, Bugaj J, de Jong M: Krenning EP: [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients.Eur J Nucl Med Mol Imaging 2001, 28:1319–1325.
21. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, Ensing GJ, Lamberts SW, Krenning EP: Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.J Nucl Med 1995, 36(4):623–627.
22. Hammond-McKibben D, Saulnier M, Zhang J, Risher N, Lake P, Weetall M: Immunologic pathways in a quantitative model of immunosuppression based on rejection of an allogeneic or xenogeneic tumor graft.Transplantation 2005, 79:889–896.
23. Law BK: Rapamycin: an anti-cancer immunosuppressant?Crit Rev Oncol Hematol 2005, 56:47–60.
24. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.J Clin Oncol 2008, 26:1596–1602.
25. North RJ: γ-Irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.Cancer Immunol Immunother 1984, 16:175–181.
26. Slone HB, Peters LJ, Milas L: Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma.J Natl Cancer Inst 1979, 63:1229–1235.
27. Demaria S, Formenti SC: Role of T lymphocytes in tumor response to radiotherapy.Front Oncol 2012, 2:95.
28. Lorimore SA, Coates PJ, Scobie GE, Milne G, Wright EG: Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects?Oncogene 2001, 20:7085–7095.
29. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L: Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.Cancer Res 2008, 68:4026–4030.
30. Dumont FJ, Su Q: Mechanism of action of the immunosuppressant rapamycin.Life Sci 1995, 58:373–395.
31. Wicker LS, Boltz RC, Matt V, Nichols EA, Peterson LB, Sigal NH: Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.Eur J Immunol 1990, 20:2277–2283.
32. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B: Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.Clin Cancer Res 2009, 15:6096–6105.
33. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.Cancer Res 2002, 62:7291–7297.
34. Fingar DC, Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.Oncogene 2004, 23:3151–3171.
35. Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, et al: Akt and p53 are potential mediators of reduced mammary tumor growth by chloroquine and the mTOR inhibitor RAD001.Biochem Pharmacol 2012, 83:480–488.
36. Sukumari-Ramesh S, Singh N, Dhandapani KM, Vender JR: mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation.Surg Neurol Int 2011, 2:22.
37. Dodson H, Wheatley SP, Morrison CG: Involvement of centrosome amplification in radiation-induced mitotic catastrophe.Cell Cycle 2007, 6:364–370.
38. Turner JH: Australian experience of radiopeptide therapy of NET.World J Nucl Med 2011, 1:52.